Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
- Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET
- 管理層將於2024年11月7日星期四上午8:30（東部時間）舉行電話會議
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
新澤西州FLORHAM PARK，2024年10月28日（環球新聞社）— phathom pharmaceuticals公司（納斯達克股票代碼：PHAT）是一家專注於開發和商業化治療腸道疾病的新穎藥物的生物製藥公司，今天宣佈將於2024年11月7日星期四上午8:30在互聯網上直播，彙報2024年第三季度財務業績並提供業務更新。
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at . A recording will be available for 90 days following the conclusion of the meeting.
可在phathom網站的「事件與演示」部分查看現場網絡直播和有關演示的更多信息。 會議結束後將提供90天的錄音。
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company's website at and follow on LinkedIn and X.
關於Phathom製藥公司
Phathom Pharmaceuticals是一家專注於開發和銷售治療胃腸疾病的新型藥物的生物製藥公司。Phathom已獲得vonoprazan的獨家許可權，它是一種首創性的鉀競爭性酸阻滯劑(PCAB)，目前在美國以VOQUEZNA(vonoprazan)片劑的形式上市，用於治療成年人非侵蝕性GERD相關的胃灼熱，成人侵蝕性GERD及相關胃灼熱的癒合和保持治癒以及VOQUEZNA TRIPLE PAk(vonoprazan片劑、阿莫西林膠囊、克拉黴素片劑)和VOQUEZNA DUAL PAk(vonoprazan片劑、阿莫西林膠囊)用於治療成人H. pylori感染。有關Phathom的更多信息，請訪問公司的網站並關注LinkedIn和X。
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
媒體聯繫方式
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
投資者聯繫信息
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
2024年phathom pharmaceuticals保留所有權利。VOQUEZNA，VOQUEZNA DUAL PAk，VOQUEZNA TRIPLE PAk，Phathom Pharmaceuticals及其各自的標誌是Phathom Pharmaceuticals，Inc.的註冊商標。
